arrow
E

Elise A. Chong

university of pennsylvania abramson cancer center
H指数:29
被引数:6,272

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia

化疗初治慢性淋巴细胞白血病患者中霍奇金淋巴瘤的转化

2026-09-260
OAAI
Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

出版更正:CD19 CAR T细胞在B细胞淋巴瘤中的十年持久性

2026-08-260
OAAI
Decade-long persistence of CD19 CAR T cells in B cell lymphomas

CD19 CAR T细胞在B细胞淋巴瘤中的十年持续性

2026-08-100
OA
Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy

初始CD4+ T细胞和CART输注时的疾病状态与接受二线CAR T疗法的大B细胞淋巴瘤患者的真实世界临床结局相关

2026-05-150
OAAI
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis

CAR T细胞疗法后套细胞淋巴瘤疾病进展的治疗与结局:一项多中心分析

2025-08-070
OAAI
Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sezary syndrome
2025-03-010
PRE
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL

未接受过既往化疗免疫疗法治疗的Richter转化CLL患者的结局

2025-02-201
OA
Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy

经嵌合抗原受体修饰的T细胞治疗的大b细胞淋巴瘤患者免疫效应细胞相关神经毒性综合征后神经系统症状延长

2025-01-010
PRE
Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

CAR-T疗法后疾病进展的复发或难治性套细胞淋巴瘤患者的治疗方案与结局:一项多中心分析

BLOOD
IF23.1
2024-11-050
PRE
Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

霍奇金淋巴瘤转化:在接受过无既往化疗的CLL/SLL患者中的转化结局——来自现代治疗时代的多中心回顾性研究

BLOOD
IF23.1
2024-11-050
PRE
Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

广谱抗生素暴露对B细胞淋巴瘤CAR-T治疗效果的影响:一项多中心国际研究

BLOOD
IF23.1
2024-11-050
PRE
Efficacy and Safety of Anti-CDI9 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

抗CDI9和抗BCMA嵌合抗原受体(CAR)T细胞疗法在自身免疫性疾病、淋巴瘤或骨髓瘤患者中的疗效与安全性

BLOOD
IF23.1
2024-11-050
PRE